Literature DB >> 7538305

Influence of gonadal hormones on sexual differences in sensitivity to methamphetamine-induced neurotoxicity.

Y L Yu1, G C Wagner.   

Abstract

The administration of high doses of methamphetamine to mice causes long-lasting depletions of striatal dopamine to a greater extent in males than in females. Likewise, the incidence of Parkinson's disease is higher in males than in females. The present study investigated the roles of estrogen and testosterone in mediating the dopamine depletion induced by methamphetamine. Male and female mice received four cumulative SC doses of methamphetamine (10 mg/kg) at two hour intervals and were sacrificed two weeks later for HPLC analysis of striatal monoamines. Intact male mice were found to have a 76% dopamine depletion, which was significantly greater than the 37% depletion exhibited by the intact female mice. Neither removal of the ovaries nor removal of the testes one month prior to the methamphetamine treatment significantly changed the magnitude of the methamphetamine-induced dopamine depletion. Thus, the reduced sensitivity of female mice to methamphetamine may be independent of physiological gonadal hormones.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7538305     DOI: 10.1007/bf02260942

Source DB:  PubMed          Journal:  J Neural Transm Park Dis Dement Sect        ISSN: 0936-3076


  12 in total

Review 1.  Estrogen as neuroprotectant of nigrostriatal dopaminergic system: laboratory and clinical studies.

Authors:  Dean Dluzen; Martin Horstink
Journal:  Endocrine       Date:  2003-06       Impact factor: 3.633

2.  Effects of age, gender, and gonadectomy on neurochemistry and behavior in animal models of Parkinson's disease.

Authors:  Andrea Tamás; Andrea Lubics; István Lengvári; Dóra Reglodi
Journal:  Endocrine       Date:  2006-04       Impact factor: 3.633

Review 3.  Estrogen actions in the brain and the basis for differential action in men and women: a case for sex-specific medicines.

Authors:  Glenda E Gillies; Simon McArthur
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

4.  Gain-of-function haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in women.

Authors:  Charles E Glatt; Angelika D Wahner; Daniel J White; Andres Ruiz-Linares; Beate Ritz
Journal:  Hum Mol Genet       Date:  2005-12-08       Impact factor: 6.150

5.  Sex differences in the acquisition of IV methamphetamine self-administration and subsequent maintenance under a progressive ratio schedule in rats.

Authors:  Megan E Roth; Marilyn E Carroll
Journal:  Psychopharmacology (Berl)       Date:  2003-12-04       Impact factor: 4.530

6.  Tamoxifen eliminates estrogen's neuroprotective effect upon MPTP-induced neurotoxicity of the nigrostriatal dopaminergic system.

Authors:  D E Dluzen; J L McDermott; L I Anderson
Journal:  Neurotox Res       Date:  2001-07       Impact factor: 3.911

7.  Sex differences in striatal dopaminergic function within heterozygous mutant dopamine transporter knock-out mice.

Authors:  Jing Ji; Dean E Dluzen
Journal:  J Neural Transm (Vienna)       Date:  2008-01-15       Impact factor: 3.575

8.  Hormone replacement therapy and risk for neurodegenerative diseases.

Authors:  Richelin V Dye; Karen J Miller; Elyse J Singer; Andrew J Levine
Journal:  Int J Alzheimers Dis       Date:  2012-04-04

9.  Peripheral vs. Central Sex Steroid Hormones in Experimental Parkinson's Disease.

Authors:  Simon McArthur; Glenda E Gillies
Journal:  Front Endocrinol (Lausanne)       Date:  2011-11-30       Impact factor: 5.555

Review 10.  Late-onset hypogonadism: Clinical evidence, biological aspects and evolutionary considerations.

Authors:  Nikolai Jaschke; Andrew Wang; Lorenz C Hofbauer; Martina Rauner; Tilman D Rachner
Journal:  Ageing Res Rev       Date:  2021-02-18       Impact factor: 10.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.